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OBJECTIVES The purpose of this study was to examine the effect of atrial fibrillation (AF) on the
immediate and long-term outcome of patients undergoing percutaneous mitral balloon
valvuloplasty (PMV).
BACKGROUND There is controversy as to whether the presence of AF has a direct negative effect on the
outcome after PMV.
METHODS The immediate procedural and the long-term clinical outcome after PMV of 355 patients
with AF were prospectively collected and compared with those of 379 patients in normal sinus
rhythm (NSR).
RESULTS Patients with AF were older (62 6 12 vs. 48 6 14 years; p , 0.0001) and presented more
frequently with New York Heart Association (NYHA) class IV (18.3% vs. 7.9%; p , 0.0001),
echocardiographic score .8 (40.1% vs. 25.1%; p , 0.0001), calcified valves under
fluoroscopy (32.4% vs. 18.8%, p , 0.0001) and with history of previous surgical
commissurotomy (21.7% vs. 16.4%; p 5 0.0002). In patients with AF, PMV resulted in
inferior immediate and long-term outcomes, as reflected in a smaller post-PMV mitral
valve area (1.7 6 0.7 vs. 2 6 0.7 cm2; p , 0.0001) and a lower event free survival
(freedom of death, redo-PMV and mitral valve surgery) at a mean follow-up time of 60
months (32% vs. 61%; p , 0.0001). In the group of patients in AF, severe post-PMV
mitral regurgitation ($31) (p 5 0.0001), echocardiographic score .8 (p 5 0.004) and
pre-PMV NYHA class IV (p 5 0.046) were identified as independent predictors of
combined events at follow-up.
CONCLUSIONS Patients with AF have a worse immediate and long-term outcomes after PMV. However, the
presence of AF by itself does not unfavorably influence the outcome, but is a marker for
clinical and morphologic features associated with inferior results after PMV. (J Am Coll
Cardiol 1999;34:1145–52) © 1999 by the American College of Cardiology
Percutaneous mitral balloon valvuloplasty (PMV) has been
established as an alternative to surgical mitral commissur-
otomy in the treatment of patients with symptomatic mitral
stenosis (1–12). Several studies have demonstrated that this
technique provides sustained clinical and hemodynamic
improvement in a selected group of patients with mitral
stenosis. Certain clinical and morphologic factors such as
age (7,10,11,13), history of previous surgical commissurot-
omy (7,10,11,14,15), presence of calcification under fluo-
roscopy (10,11,13,16), echocardiographic score (10,11,15,
17–22), New York Heart Association (NYHA) class IV at
presentation (10,11,13,15,17,21) and the presence of severe
tricuspid regurgitation (23), have been identified as predic-
tors of immediate and long-term outcome after PMV. The
development of atrial fibrillation (AF) is a common and
important sequelae in patients with mitral stenosis, and it is
associated with hemodynamic and clinical decompensation.
Previous surgical studies have demonstrated that the pres-
ence of AF is associated with suboptimal immediate and
long-term outcome after surgical mitral commissurotomy
(24–30). However, there is controversy as to whether AF is
an important independent predictor of the immediate and
long-term outcome of patients undergoing PMV. Thus, the
purpose of this study was to address this important clinical
issue by evaluating the effect of AF on the immediate and
long-term outcome of PMV in a large cohort of consecutive
patients undergoing the procedure at the Massachusetts
General Hospital.
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METHODS
Study population. The study group included 734 consec-
utive patients who underwent PMV at the Massachusetts
General Hospital between July 1986 and March 1997. Of
these 734 patients, 355 (48.4%) had AF at the time of the
procedure and 379 (51.6%) had normal sinus rhythm
(NSR). All patients were screened clinically and by trans-
thoracic echocardiography. Patients with AF and those with
previous embolic events had undergone anticoagulation
with warfarin for at least three months before consideration
for PMV. Transesophageal echocardiography was per-
formed in patients with a suboptimal transthoracic study, in
those with a history of a previous embolic event and in those
with a possible left atrial thrombus by the transthoracic
study. Patients with left atrial thrombus were treated with
warfarin for at least two to three months, and PMV was
performed only if resolution of the left atrial thrombus was
demonstrated by repeat transesophageal echocardiography.
PMV procedure. All patients underwent PMV using the
transseptal antegrade technique as previously described (1–
3), after informed consent was obtained. The double-
balloon technique was used with 621 patients and the Inoue
technique with 113 patients. The balloon combination in
the double-balloon technique was selected on the basis of
effective balloon dilating area/body surface area ratio
(EBDA/BSA), so that this ratio was .3.3 but less than 4
cm2/m2 (31,32). The maximum volume of the Inoue bal-
loon used was determined by the equation: maximum
balloon volume (mm) 5 (patient’s height (cm)/10) 1 10
(32). Before and after PMV, right and left heart pressure
measurements, including simultaneous left atrial and left
ventricular pressures and cardiac output, were performed.
Oxygen saturation of blood samples from the superior vena
cava, pulmonary artery and the aorta were measured before
and after PMV. Cardiac output was determined by the
thermodilution technique. However, where there was evi-
dence of left to right shunting (step up in oxygen saturation
between the right atrium and pulmonary artery $7%), or
when significant tricuspid regurgitation was present by
physical examination or echocardiography, cardiac output
was calculated according to the Fick principle. In the
presence of left to right shunting, the oxygen content of
the blood sample from the superior vena cava was used as
the mixed venous blood sample, and oxygen consumption
was measured by an MRM-2 oxygen consumption monitor
(Waters Instrument Inc., Rochester, Minnesota). The mi-
tral valve area was calculated using the Gorlin formula. Left
ventriculography was performed in all patients before and
after PMV to assess the severity of mitral regurgitation
using the Sellers classification (33).
Data collection and definitions. All data were prospec-
tively collected and entered into a computerized database
(InterCard, Massachusetts General Hospital, Boston, Mas-
sachusetts) (34). Demographic and clinical variables in-
cluded age, gender, body surface area, New York Heart
Association (NYHA) functional class at presentation, pres-
ence of AF and previous surgical commissurotomy. Labo-
ratory variables included the echocardiographic score, pre-
and post-PMV severity of mitral regurgitation according to
the Sellers classification using contrast left ventriculography
and the presence of fluoroscopically visible mitral valve
calcification, which was graded from 0 to 4, as previously
described (16). Procedural-related variables included the
type of technique (double balloon vs. Inoue), EBDA/BSA
and the following hemodynamic variables before and after
PMV: mean pulmonary artery and left atrial pressures, mean
mitral valve gradient, cardiac output and calculated mitral
valve area.
Prospectively collected procedure related complications
included death, mitral valve replacement (MVR), pericar-
dial tamponade, thromboembolism, third-degree atrioven-
tricular block, post-PMV mitral regurgitation $31 and left
to right shunt with a pulmonary/systemic ratio (QP/QS)
.1.5:1. Procedure-related death was defined as in-hospital
death that was directly related to the PMV procedure.
Successful outcome of PMV was defined as a post-PMV
mitral valve area $1.5 cm2, without .21 increase in the
severity of mitral regurgitation, and post-PMV mitral re-
gurgitation ,31 and without left to right shunt with
QP/QS .1.5:1 after the procedure (18).
Follow up. Follow-up information was obtained by trained
medical personnel using direct telephone interviews with
the patients or follow-up visits by physicians. This informa-
tion included survivorship, MVR, redo PMV and clinical
evaluation according to the NYHA classification of conges-
tive heart failure symptoms. The interviewer was blinded to
the procedural variables and immediate outcome after
PMV. When necessary, local physicians were contacted for
further information and medical records were reviewed.
Statistical analysis. Continuous variables are expressed as
mean 6 standard deviation (SD), and categorical variables
as percent. Student t test and chi-square analysis were
carried out for comparison of continuous and categorical
variables, respectively. p Values #0.05 were considered
significant. Demographic, clinical, echocardiographic, pro-
cedural and angiographic variables were tested to determine
significant (p , 0.05) univariate correlates of immediate
Abbreviations and Acronyms
AF 5 atrial fibrillation
EBDA/BSA 5 effective balloon dilating area/body
surface area
MVR 5 mitral valve replacement
NSR 5 normal sinus rhythm
NYHA 5 New York Heart Association
PMV 5 percutaneous mitral balloon valvuloplasty
QP/QS 5 pulmonary to systemic flow ratio
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success in both the overall and in the AF groups. Multiple
stepwise logistic regression analyses of these significant
variables were performed to identify independent predictors
of immediate success in the overall group of patients and in
the group of patients in AF.
Kaplan-Meier estimates were used to determine total
survival and event-free survival (survival with freedom from
MVR and redo PMV) for both groups of patients and
compared by log rank test. Cox proportional hazards regres-
sion analyses using backward elimination were used to
identify independent correlates of mortality and event-free
survival in the AF group. Kaplan-Meier plots with log rank
test of demographic, clinical and procedural variables were
generated to determine potential confounders of the rela-
tionship between AF and mortality and between AF and
event-free survival. All variables with significant differences
in mortality or event-free survival by log rank test were
entered into separate proportional hazards models. The
variables included in the analyses were age, gender, NYHA
functional class at presentation, history of previous surgical
commissurotomy, fluoroscopic presence of calcium $21,
echocardiographic score, technique of PMV, pre- and
post-PMV mitral valve area, pre-PMV mitral regurgitation
$11, post-PMV mitral regurgitation $31 and pre- and
post-PMV mean pulmonary artery pressure. All variables
were initially included in the regression equations. The least
significant variable was eliminated first from the models,
and the remaining variables were examined again to deter-
mine the next least significant variable for removal. This
procedure was continued with removal of variables in a
stepwise fashion until only significant variables (p # 0.05)
remained in the models. The models were also tested by
forward stepping elimination yielding the same independent
predictors. All analyses were performed using SAS software
version 6.10 (SAS Institute, Cary, North Carolina).
RESULTS
Preprocedural clinical and morphologic variables. Base-
line demographic and clinical characteristics of the two
groups of patients are shown in Table 1. Patients in AF
were older (62 6 12 vs. 48 6 14 years, p , 0.0001) and
presented more frequently with NYHA functional class IV
(18.3% vs. 7.9%, p , 0.0001), history of previous surgical
commissurotomy (21.7% vs. 16.4%, p 5 0.0002), $21
grade of mitral calcification by fluoroscopy (32.4% vs.
18.8%, p , 0.0001), echocardiographic score .8 (40.1% vs.
25.1%, p , 0.0001) and pre-PMV mitral regurgitation
$11 (51.4% vs. 38.8%, p 5 0.0006).
Hemodynamic variables. Hemodynamic findings before
and after PMV are shown in Table 2. Before PMV, patients
in AF had lower pre-PMV mitral valve area (0.86 6 0.3 vs.
0.94 6 0.3 cm2, p 5 0.0002). After PMV, patients in AF
had significantly lower post-PMV mitral valve area (1.7 6
0.7 cm2 vs. 2.0 6 0.7 cm2, p , 0.0001). In addition, the
mean pulmonary artery (31 6 10 vs. 27 6 11 mm Hg, p ,
0.0001) and mean left atrial (17 6 6 vs. 15 6 6 mm Hg, p ,
0.0001) pressures were significantly higher after PMV in the
AF group. There was no significant difference in the type of
technique of PMV (double balloon: 86.5% in the AF group
and 82.9% in the NSR group, p 5 NS) or the EBDA/BSA
(AF group: 3.65 6 0.5, NSR group: 3.67 6 0.5, p 5 NS)
between the two groups.
Immediate outcome and complications. The immediate
procedural results and in-hospital outcomes are shown in
Table 3.
Procedural success. Patients in the AF group have a lower
procedural success (61.1% vs. 76.1%, p , 0.0001). Univar-
iate predictors of procedural success in the AF group







Age 62 6 12 48 6 14 , 0.0001
Female gender 282 (80%) 319 (84%) NS
NYHA
Class I 1 (0.3%) 5 (1.3%) NS
Class II 65 (18.3%) 119 (31.4%) , 0.0001
Class III 224 (63.1%) 225 (59.3%) NS
Class IV 65 (18.3%) 30 (7.9%) , 0.0001
Echo score #8 212 (59.9%) 284 (74.9%) , 0.0001
Echo score .8 142 (40.1%) 95 (25.1%) , 0.0001
Fluoroscopic calcium
$21
114 (32.4%) 71 (18.8%) , 0.0001
Prior commissurotomy 77 (21.7%) 43 (16.4%) 0.0002
Mitral regurgitation 11 145 (41.2%) 133 (35.4%) 0.003
Mitral regurgitation 21 34 (9.6%) 12 (3.2%) 0.0003
All data are expressed as mean value 6 SD or number (%) of patients.
AF 5 atrial fibrillation; NS 5 not significant; NSR 5 normal sinus rhythm;
NYHA 5 New York Heart Association.







MG pre-PMV (mm Hg) 13 6 5 16 6 6 , 0.0001
MG post-PMV (mm Hg) 5 6 3 5 6 3 NS
CO pre-PMV (liter/min) 3.4 6 0.9 4.3 6 1.1 , 0.0001
CO post-PMV (liter/min) 4 6 1 4.9 6 1.3 , 0.0001
MVA pre-PMV (cm2) 0.86 6 0.3 0.94 6 0.3 0.0002
MVA post-PMV (cm2) 1.7 6 0.7 2.0 6 0.7 , 0.0001
PA pre-PMV (mm Hg) 37 6 12 36 6 14 NS
PA post-PMV (mm Hg) 31 6 10 27 6 11 , 0.0001
LA pre-PMV (mm Hg) 24 6 7 25 6 7 NS
LA post-PMV (mm Hg) 17 6 6 15 6 6 , 0.0001
EBDA/BSA (cm2/m2) 3.65 6 0.5 3.67 6 0.5 NS
Technique
Double balloon 307 (86.5%) 314 (82.9%) NS
Inoue 48 (13.5%) 65 (17.1%) NS
AF 5 atrial fibrillation; CO 5 cardiac output; EBDA/BSA 5 effective balloon
dilating area/body surface area; LA 5 mean left atrium pressure; MG 5 mitral
gradient; MVA 5 mitral valve area; NSR 5 normal sinus rhythm; PA 5 mean
pulmonary artery pressure; PMV 5 percutaneous mitral balloon valvotomy.
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included age, male gender, history of previous commissur-
otomy, NYHA functional status at presentation, fluoro-
scopic mitral valve calcification, echocardiographic score,
pre-PMV mitral valve area, pre-PMV mitral regurgitation
and pre-PMV mean pulmonary artery pressure. Multiple
stepwise logistic regression analysis identified pre-PMV
mitral valve area (p # 0.0001), echocardiographic score #8
(p 5 0.001), male gender (p 5 0.038) and absence of
previous surgical commissurotomy (p 5 0.048) as indepen-
dent predictors of procedural success in patients in AF.
In the overall population, the absence of AF was identi-
fied as univariate predictor of procedural success (p 5
0.0001). Other univariate predictors included younger age
(p 5 0.0001), male gender (p 5 0.0003), absence of
previous commissurotomy (p 5 0.0078), lower NYHA
functional status at presentation (p 5 0.0001), lower fluo-
roscopic mitral valve calcification (p 5 0.0001), lower
echocardiographic score (p 5 0.0001), the technique of
(double-balloon technique; p 5 0.05), larger pre-PMV
mitral valve area (p 5 0.0001), lower pre-PMV mitral
regurgitation (p 5 0.0001) and lower pre-PMV mean
pulmonary artery pressure (p 5 0.001). However, the
presence of AF was not an independent predictor of success.
Multiple stepwise logistic regression analysis identified pre-
PMV mitral valve area (odds ratio [OR] 138, confidence
intervals [CI] 43.8 to 466, p , 0.0001), echocardiographic
score #8 (OR 1.92; CI 1.26 to 2.94, p 5 0.002), male
gender (OR 2.32; CI 1.37 to 4.16, p 5 0.002), absence of
previous surgical commissurotomy (OR 1.79; CI 1.09 to
2.94, p 5 0.01) and younger age (OR 6.25; CI 2.5 to 16.6,
p 5 0.0002) as independent predictors of procedural suc-
cess.
In-hospital mortality. There were 13 (1.8%) in-hospital
deaths, and 4 (0.5%) of them were procedure-related deaths.
The four procedure related deaths occurred as follows: one
patient who was brought to the catheterization laboratory in
cardiogenic shock who underwent emergent PMV and died
despite a technically successful and uncomplicated proce-
dure; Another patient who died due to left ventricular
perforation and development of tamponade 12 h after
PMV; a third patient who died during emergent MVR from
intractable right ventricular failure (11) and a fourth patient
who presented with cardiogenic shock due to severe aortic
and mitral stenosis, underwent emergent PMV and percu-
taneous aortic valvuloplasty and died due to persistent
cardiogenic shock and severe mitral regurgitation. The
causes of the other nine in-hospital deaths were the follow-
ing. One patient died suddenly one day after PMV with the
autopsy showing an acute inferior wall myocardial infarc-
tion; one patient died from electromechanical dissociation
after percutaneous aortic valvotomy, which had been under-
taken 24 h after PMV; another patient who was not a
surgical candidate died from persistent cardiogenic shock
within 24 h after a suboptimal compassionate PMV; one
patient died from complications after surgical treatment of a
subdural hematoma; one patient with end stage chronic
obstructive pulmonary disease died from respiratory failure;
and four patients died from multisystem organ failure due to
sepsis unrelated to PMV. Although all of the procedure-
related deaths occurred in the AF group, this difference was
not statistically significant. However, the total in-hospital
mortality was higher in the AF group (3.1% vs. 0.5%, p 5
0.01).
Mitral regurgitation. There were no differences between
the AF and NSR groups in the incidence of 31 (7.2% vs.
5.4%, p 5 NS) or 41 (2.6% vs. 4%, p 5 NS) post-PMV
mitral regurgitation as assessed by left ventriculography
using the Sellers criteria.
MVR. Twenty-four patients (3.2%) underwent MVR dur-
ing their hospitalization. Eighteen patients underwent
MVR due to development of severe mitral regurgitation
(31 or 41) after PMV. Two patients underwent MVR
during surgical treatment for pericardial tamponade and
ongoing hemodynamic deterioration despite pericardiocen-
tesis. In one patient, the pulmonary artery was entered
during transseptal catheterization, requiring surgical re-
moval of the catheter and MVR. Finally, three patients
underwent MVR due to suboptimal post-PMV mitral valve
area. Emergent MVR (less than 24 h after PMV) was
required in nine (1.2%) patients. There were no significant
differences in the incidence of emergent (1.1% vs. 1.3%, p 5
NS) or total in hospital MVR (2.8% vs. 3.7%, p 5 NS)
between the AF and NSR groups.
Other complications. Pericardial tamponade occurred in 6
patients (4 patients [1.1%] in the AF group and 2 patients
[0.5%] in the NSR group, p 5 NS). As described earlier,
one patient developed tamponade from left ventricular
perforation. Two patients continued to have hemodynamic
deterioration despite emergent pericardiocentesis and re-
quired emergent surgical drainage. The other three patients




(n 5 379) p
Procedural success 212 (61.1%) 284 (76.1%) , 0.0001
Procedural death 4 (1.1%) 0 (0%) NS
In-hospital death 11 (3.1%) 2 (0.5%) 0.01
MR grade post-PMV
31 25 (7.2%) 20 (5.4%) NS
41 9 (2.6%) 15 (4%) NS
Emergent MVR 4 (1.1%) 5 (1.3%) NS
In-hospital MVR 10 (2.8%) 14 (3.7%) NS
Pericardial tamponade 4 (1.1%) 2 (0.5%) NS
AV block 0 2 (0.5%) NS
QP/QS .1.5 22 (6.2%) 19 (5%) NS
Thromboembolism 7 (2%) 3 (0.8%) NS
AF 5 atrial fibrillation; AV 5 atrio-ventricular; MR 5 mitral regurgitation; MVR 5
mitral valve replacement; NSR 5 normal sinus rhythm; PMV 5 percutaneous mitral
balloon valvotomy; QP/QS 5 pulmonary to systemic flow ratio.
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were successfully treated with pericardiocentesis in the
catheterization laboratory and the PMV was completed
successfully. A left to right shunt with a pulmonary to systemic
flow ratio .1.5:1 was detected in 22 (6.2%) patients in AF
versus 19 (5%) of the patients in NSR group (p 5 NS).
Thromboembolic events occurred in 10 (1.3%) of the
overall population: seven (2%) occurred in the AF group and
three (0.8%) in the NSR group (p 5 NS). A cerebrovascular
event occurred in five patients, with four of them having
complete neurologic recovery at the time of discharge. Four
patients had embolism to the lower extremities, requiring
surgical intervention. Finally, one patient had an embolic
non-Q wave myocardial infarction. He was treated conser-
vatively and had normal left ventricular function at dis-
charge. Finally, two (0.3%) of the patients in the NSR group
developed complete atrioventricular block; one responded to
atropine administration, and the other required temporary
pacemaker insertion for 24 h.
Clinical follow up. Clinical follow up information was
available in 672 (91.6%) of the overall patient population at
a median follow up time of 66.2 6 0.9 months. The follow
up was completed in 329 (92.7%) of the patients in the AF
group and 343 (90.5%) of the patients in the NSR group. In
the AF group, cumulative events included 51 deaths, 79
MVR and 20 redo PMV, accounting for a total of 150
patients with combined events (death, MVR or redo PMV.
Of the remaining 179 patients that were free of combined
events, 163 (91.1%) were in NYHA class I or II and 16
(8.9%) patients were in class III or IV. In the NSR group,
cumulative events included 26 deaths, 81 MVR and 21 redo
PMV, accounting for a total of 128 patients with combined
events at follow-up. Of the remaining 215 patients that
were free of any event, 199 (92.6%) were in NYHA class I
or II and 16 (7.4%) were in class III or IV.
Figure 1 shows estimated actuarial total survival curves
for patients in AF and NSR. Actuarial survival rates
throughout the follow-up period were significantly better in
patients in NSR than those in AF. Survival rates were 89.4%
for the NSR group and 68% for the AF group at a mean
follow-up time of 60 months (p , 0.0001). Freedom from
MVR (72.3% vs. 56.9%; p 5 0.02) and freedom from redo
PMV (94.3% vs. 83.3%; p 5 0.03) at 60-month follow-up
were also significantly higher for patients in the NSR group.
Estimated actuarial event-free survival curves (no death,
MVR or redo PMV) are shown in Figure 2. Event-free
survival rates were significantly higher in the NSR group
throughout the follow-up period. At a mean follow-up time
of 60 months, event-free survival was 61% for the NSR
group and 32% for the AF group (p , 0.0001).
Cox regression analysis identified post-PMV mitral re-
gurgitation $31 (p 5 0.0001), echocardiographic score .8
(p 5 0.004) and pre-PMV NYHA class IV (p 5 0.046) as
independent predictors of combined events at long-term
follow-up in the AF group. Furthermore, Cox regression
analysis identified pre-PMV NYHA functional class IV
(risk ratio [RR] 3.50; CI 1.92 to 6.49; p , 0.0001), age (RR
1.066; CI 1.03 to 1.099) and post-PMV mean pulmonary
artery pressure (RR 1.033; CI 1.01 to 1.06) as independent
predictors of mortality at long-term follow-up in the AF
group.
In the overall patient population, the presence of AF was
not an independent predictor of combined events at long-
term follow-up. Cox regression analysis identified post-
PMV mitral regurgitation $31 (RR 2.88; CI 2.05 to 3.97;
p , 0.0001), echocardiographic score $8 (RR 1.48; CI 1.12
Figure 1. Kaplan-Meier survival curves of patients in normal sinus
rhythm versus atrial fibrillation after PMV. Numbers at the
bottom represent patients alive and uncensored at the end of each
of period of observation for 343 patients in NSR (top) and 329
patients in AF (bottom) entered at the outset of the study. AF 5
atrial fibrillation; NSR 5 normal sinus rhythm; PMV 5 percuta-
neous balloon mitral valvuloplasty.
Figure 2. Kaplan-Meier event-free survival curves of patients in
NSR versus AF after PMV. Numbers at the bottom represent
patients alive and free of combined events (mitral valve surgery and
redo-PMV) uncensored at the end of each of period of observation
for 343 patients in NSR (top) and 329 patients in AF (bottom)
entered at the outset of the study. Abbreviations as in Figure 1.
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to 1.97; p 5 0.005), age (RR 1.02; CI 1.01 to 1.03; p ,
0.0001), post-PMV MVA (RR 0.78; CI 0.63 to 0.93; p 5
0.01) and post-PMV mean pulmonary artery pressure (RR
1.02; CI 1.01 to 1.03; p 5 0.0001) as independent predic-
tors of combined events at long-term follow-up.
Echocardiographic score, AF and immediate and long-
term outcomes. In the AF group, patients with echocar-
diographic scores #8 had a superior immediate success rate
(72% vs. 44.5%; p , 0.0001) than patients with echocar-
diographic scores .8. Furthermore, in this group of AF
patients, survival (83.5% vs. 37.9%; p , 0.0001) and
event-free survival (43.5% vs. 16.3%; p , 0.0001) at
60-month follow up were significantly higher in patients
with echocardiographic scores #8 (Figs. 3 and 4). The
negative effect of AF in the long-term outcome of patients
undergoing PMV is also present in patients with echocar-
diographic scores #8. At a similar follow-up time of 60
months, patients in AF with echocardiographic scores #8
had a worse survival (83.5% vs. 93.7%) and event-free
survival (43.5% vs. 67.9%) than those patients in NSR with
echocardiographic scores #8 (p 5 0.0007).
DISCUSSION
The present study demonstrates that patients with rheu-
matic mitral stenosis in AF have a worse immediate and
long-term outcome after PMV. However, the presence of
AF by itself does not unfavorably influence the outcome, but
is a marker for clinical and morphologic features associated
with inferior results after PMV.
AF and immediate outcome of PMV. Although the
presence of AF is not an independent predictor of proce-
dural success, patients in AF have an inferior immediate
hemodynamic outcome of PMV as reflected in a lower
procedural success rate (61% vs. 76%, p , 0.0001) and a
smaller post-PMV mitral valve area (1.7 6 0.7 cm2 vs. 2 6
0.7 cm2, p , 0.0001). However, there were not significant
differences in the post-PMV incidence of severe mitral
regurgitation, or left to right shunting between the two groups
of patients. A higher incidence of clinical and morphologic
characteristics associated with suboptimal results after PMV in
this patient cohort account for these results. Although the
presence of AF was associated with higher in-hospital mortal-
ity, other procedural complications such as in-hospital MVR,
pericardial tamponade and thromboembolic events were sim-
ilar in the two groups of patients.
AF and long-term follow-up after PMV. The present
study also demonstrates that the presence of AF had a
negative effect on the clinical follow-up of patients under-
going PMV. Patients with AF had lower survival and
event-free survival than patients with NSR. At a mean
follow-up time of 60 months, survival and event-free
survival were 89.4% and 61%, respectively, for NSR group
and only 68% and 32% for the AF group (p , 0.0001).
Again, the presence of AF was not an independent predictor
of event-free survival. Therefore, the inferior immediate and
long-term outcome of PMV in patients with mitral stenosis
who have AF is more likely related to the presence of
clinical and morphologic characteristics associated with
inferior results after PMV. In the present study, patients in
AF were older and presented more frequently with echo-
cardiographic scores .8, NYHA functional class IV, calci-
fied mitral valves under fluoroscopy and with a previous
history of surgical mitral commissurotomy. Previous studies
have demonstrated that older age (7,10,11,13,18,21,22),
NYHA class IV at presentation (10,11,13,15,17,21) high
Figure 3. Kaplan-Meier survival curves of patients in AF with
echocardiographic score #8 and .8 after PMV. Numbers at the
bottom represent patients alive and uncensored at the end of each
of period of observation for 206 patients in NSR (top) and 123
patients in AF (bottom) entered at the outset of the study.
Abbreviations as in Figure 1.
Figure 4. Kaplan-Meier survival and event-free survival curves of
patients in AF with echocardiographic score .8 after PMV.
Numbers at the bottom represent patients alive and free of
combined events (mitral valve surgery or redo-PMV) uncensored
at the end of each of period of observation for 206 patients in NSR
(top) and 123 patients in AF (bottom) entered at the outset of the
study. Abbreviations as in Figure 1.
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echocardiographic score (.8) (10,11,15,17–22), history of
prior surgical commissurotomy (7,10,11,14,15,18), and flu-
oroscopically visible mitral valve calcification (10,11,13,
16,18,35) are associated with suboptimal immediate and
long-term results of PMV. In addition, the worse immedi-
ate hemodynamic outcome of PMV in the AF group
contributes to the worse long-term outcome of this group of
patients. Smaller post-PMV mitral valve area (21,22,36)
and higher post-PMV pulmonary artery pressures
(13,21,36) have been identified as important predictors of
combined events during long-term follow up after PMV.
Accordingly, it is reasonable to assume that the presence
of AF represents a marker for more severe or long-standing
mitral stenosis, and it is inevitably associated with clinical
and morphologic features that adversely affect the immedi-
ate and long-term outcome after PMV. Previous studies
have demonstrated that structural changes in the left atrial
myocardium are important for the development of AF, and
that the prevalence of AF correlates with the severity of
myocardial derangement in the left atrium (37–40). The
strong association between age and AF in mitral stenosis
suggests that the structural changes in the atrial myocar-
dium that predispose to AF are time-dependent. Therefore,
the chronicity of the underlying rheumatic disease process in
patients with atrial fibrillation is more likely to be associated
with more severe mitral valve deformity and calcification.
Predictors of immediate and follow-up results in patients
in AF. Although PMV results in a good immediate out-
come in only 61% of patients in AF and a five-year
event-free survival of 32%, we identified independent pre-
dictors that would define a subgroup of patients in the AF
group that would have the best chance of immediate success
and sustained long-term benefit from PMV. Among these
predictors, the echocardiographic score remains the most
important independent preprocedural determinant of im-
mediate and long-term outcome and the major factor that
the clinician should take into account before recommending
PMV in patients with mitral stenosis and AF. A sustained
long-term benefit can be predicted primarily by the presence
of a low echocardiographic score and a successful PMV
procedure. Although the present study demonstrates that
patients in AF with echocardiographic scores #8 had a
worse survival and event-free survival than those patients in
NSR with echocardiographic scores #8, the presence of AF
does not necessarily predict inferior immediate and long-
term outcome after PMV. Patients with AF with echocar-
diographic scores #8 have immediate and long-term out-
comes comparable with patients in NSR.
Comparison with previous studies. Previous studies on
the influence of AF on the immediate success and long-term
outcome after PMV have been controversial. We have
previously reported that the presence of AF was an inde-
pendent predictor of suboptimal result after PMV in a
smaller group of patients (19,20). The negative influence of
AF was also demonstrated in a group of patients with
echocardiographic scores $10, where AF was the only
predictor of sub-optimal result (41), as well as in a subgroup
of patients with previous surgical commissurotomy, where
AF was a univariate predictor of immediate and short-term
outcome. Hung et al. (42) reported that AF was a univariate
predictor of suboptimal immediate result but not an inde-
pendent predictor by multivariate analysis. Iung et al. (43)
identified sinus rhythm as univariate predictor of good
functional results five years after a successful procedure, but
the multivariate analysis failed to demonstrate rhythm as a
independent predictor of long-term success. Pan et al. (35)
identified the presence of AF as an independent predictor of
late success. Conversely, in the larger series from the
NHLBI registry of percutaneous balloon mitral commissur-
otomy, AF was not an independent predictor of procedural
success or long-term outcome at 4 years of follow-up
(21,44). Other reports also did not reveal any association
between AF and suboptimal immediate or long-term out-
come after percutaneous balloon valvotomy (4,5,7,17,22).
The inconsistency of the results of these studies is more
likely explained by the size of the patient population
included in each study as well as different baseline clinical
and morphologic characteristics of the patients.
Our results agree with previous surgical studies showing
the negative influence of AF on the immediate and long-
term outcome of patients with mitral stenosis undergoing
closed and open surgical commissurotomy for the treatment
of symptomatic mitral stenosis. They demonstrated that the
presence of AF had an adverse effect on operative mortality
and long-term survival and event-free survival after open
and closed commissurotomy (24–30) and was, in some of
them, an independent predictor of outcome. In a clinical
study of 1,000 consecutive cases of mitral stenosis followed
up to nine years, Ellis et al. (28) identified the presence of
NSR as an important predictor of improvement after closed
surgical commissurotomy. In a study of 267 patients fol-
lowed during 20 years after transventricular commissurot-
omy, Rihal et al. (29) identified AF as an independent
predictor of long-term survival. In the study by Scalia et al.
(30) with a follow-up time up to 22 years after closed or
open mitral commissurotomy, AF was identified as an
univariate predictor of survival and effective palliation.
Conclusions. The present study demonstrated that the
presence of AF is associated with inferior immediate and
long-term outcome after PMV. Analysis of preprocedural
and procedural characteristics revealed that this association
is most likely explained by the presence of multiple factors
in the AF group that adversely affect the immediate and
long-term outcome of PMV. Therefore, the presence of AF
should not be the only determinant in the decision process
regarding treatment options in a patient with rheumatic
mitral stenosis because its presence does not necessarily
predict adverse outcome. An echocardiographic score #8
primarily identifies a subgroup of patients in AF in whom
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percutaneous balloon valvotomy is very likely to be success-
ful and provide good long-term results.
Study limitations. Follow-up information was not avail-
able in 8.4% of the patient population. Because it is likely
that patients may have not received follow up due to an
adverse event, this may have affected the results of our study.
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